Corvus Pharmaceuticals, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2021 Annual Meeting of Stockholders held by Corvus Pharmaceuticals, Inc. on June 15, 2021. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Burlingame, California.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial performance data. The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Voting Results
As of the record date (April 19, 2021), there were 38,309,551 shares of common stock outstanding. A total of 27,719,139 shares were voted at the meeting. The stockholders approved two proposals:
- Proposal 1: Election of Directors
- Scott W. Morrison: 20,548,120 votes For; 169,572 votes Withheld; 7,001,447 Broker Non-Votes.
- Edith P. Mitchell, M.D.: 20,572,477 votes For; 145,215 votes Withheld; 7,001,447 Broker Non-Votes.
- Proposal 2: Ratification of Independent Registered Accounting Firm
- PricewaterhouseCoopers LLC was ratified for the fiscal year ending December 31, 2021.
- Votes For: 27,550,167; Votes Against: 47,149; Abstain: 121,823.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on business outlook, specific risks, contingencies, or unusual items. The report is limited to the tabulation of stockholder votes.
Key Facts for Investor Verification
- Verify the election of Class II directors Scott W. Morrison and Edith P. Mitchell, M.D., serving until the 2024 Annual Meeting.
- Confirm the ratification of PricewaterhouseCoopers LLC as the independent auditor for fiscal year 2021.
- Note the significant number of Broker Non-Votes (7,001,447) on the director election proposal.
- Review the Definitive Proxy Statement on Schedule 14A filed on April 20, 2021, for detailed background on the proposals.